356 related articles for article (PubMed ID: 19663597)
1. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment.
Sundar S; Agrawal N; Arora R; Agarwal D; Rai M; Chakravarty J
Clin Infect Dis; 2009 Sep; 49(6):914-8. PubMed ID: 19663597
[TBL] [Abstract][Full Text] [Related]
2. Injectable paromomycin for Visceral leishmaniasis in India.
Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
[TBL] [Abstract][Full Text] [Related]
3. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
4. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions.
Sundar S; Chakravarty J; Rai VK; Agrawal N; Singh SP; Chauhan V; Murray HW
Clin Infect Dis; 2007 Sep; 45(5):556-61. PubMed ID: 17682988
[TBL] [Abstract][Full Text] [Related]
5. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
[TBL] [Abstract][Full Text] [Related]
8. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
Sundar S; Chakravarty J; Agarwal D; Rai M; Murray HW
N Engl J Med; 2010 Feb; 362(6):504-12. PubMed ID: 20147716
[TBL] [Abstract][Full Text] [Related]
9. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.
Sundar S; Jha TK; Sindermann H; Junge K; Bachmann P; Berman J
Pediatr Infect Dis J; 2003 May; 22(5):434-8. PubMed ID: 12792385
[TBL] [Abstract][Full Text] [Related]
10. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India.
Jha TK; Sundar S; Thakur CP; Felton JM; Sabin AJ; Horton J
Am J Trop Med Hyg; 2005 Dec; 73(6):1005-11. PubMed ID: 16354802
[TBL] [Abstract][Full Text] [Related]
11. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya.
Wasunna MK; Rashid JR; Mbui J; Kirigi G; Kinoti D; Lodenyo H; Felton JM; Sabin AJ; Albert MJ; Horton J
Am J Trop Med Hyg; 2005 Nov; 73(5):871-6. PubMed ID: 16282296
[TBL] [Abstract][Full Text] [Related]
12. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.
Olliaro P; Sundar S
Trop Med Int Health; 2009 Jan; 14(1):88-92. PubMed ID: 19121150
[TBL] [Abstract][Full Text] [Related]
13. Oral miltefosine for the treatment of Indian visceral leishmaniasis.
Sundar S; Jha TK; Thakur CP; Bhattacharya SK; Rai M
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S26-33. PubMed ID: 16730038
[TBL] [Abstract][Full Text] [Related]
14. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
[TBL] [Abstract][Full Text] [Related]
15. A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis.
Das VN; Ranjan A; Sinha AN; Verma N; Lal CS; Gupta AK; Siddiqui NA; Kar SK
J Assoc Physicians India; 2001 Jun; 49():609-13. PubMed ID: 11584934
[TBL] [Abstract][Full Text] [Related]
16. Oral miltefosine for Indian visceral leishmaniasis.
Sundar S; Jha TK; Thakur CP; Engel J; Sindermann H; Fischer C; Junge K; Bryceson A; Berman J
N Engl J Med; 2002 Nov; 347(22):1739-46. PubMed ID: 12456849
[TBL] [Abstract][Full Text] [Related]
17. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
Sundar S; Jha TK; Thakur CP; Mishra M; Singh VP; Buffels R
Clin Infect Dis; 2003 Sep; 37(6):800-4. PubMed ID: 12955641
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis.
Sundar S; Singh A; Agarwal D; Rai M; Agrawal N; Chakravarty J
Am J Trop Med Hyg; 2009 May; 80(5):700-3. PubMed ID: 19407109
[TBL] [Abstract][Full Text] [Related]
19. Amphotericin B therapy in children with visceral leishmaniasis: daily vs. alternate day, a randomized trial.
Singh UK; Prasad R; Jaiswal BP; Singh PK; Thakur CP
J Trop Pediatr; 2010 Oct; 56(5):321-4. PubMed ID: 20065047
[TBL] [Abstract][Full Text] [Related]
20. Short-course of oral miltefosine for treatment of visceral leishmaniasis.
Sundar S; Makharia A; More DK; Agrawal G; Voss A; Fischer C; Bachmann P; Murray HW
Clin Infect Dis; 2000 Oct; 31(4):1110-3. PubMed ID: 11049800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
